Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients

BACKGROUND: The current maintenance dose (10,000 AUeq/monthly) of a subcutaneous allergoid for house dust mite (HDM) immunotherapy has previously shown significant clinical efficacy in patients with HDM induced allergic rhinitis or rhinoconjunctivitis. In order to comply with the 2009 EMA guidelines...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rieker-Schwienbacher, Juliane, Nell, Marja J, Diamant, Zuzana, van Ree, Ronald, Distler, Andreas, Boot, Johan D, Kleine-Tebbe, Jörg
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2013
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3658910/
https://ncbi.nlm.nih.gov/pubmed/23657148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2045-7022-3-16
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi